Please login to the form below
cancer
This page shows the latest cancer news and features for those working in and with pharma, biotech and healthcare.
In person with...Jenny Squibbs
What has been your career highlight to date? I went to the US to visit patients living with kidney cancer. ... I was lucky enough to have the opportunity to sit with these patients and hear their stories of what it was like to live with incurable kidney
Latest news
-
Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
trace of the cancer left – offering hope of a long term remission or even a cure. ... Gilead’s managing director for the UK and Ireland Hilary Hutton-Squire told PME that she is confident of agreeing a deal, with access via the Cancer Drugs Fund (CDF)
-
London cancer hub launched by Cancer Research UK
Francis Crick Institute – bringing together researchers who will collaborate on cancer biotherapeutics including immunotherapies such as CAR-T. ... A key project will be investigating the impact of cancer progression on the immune system, says CRUK.
-
Tox trouble stalls Sosei/Allergan Alzheimer’s drug
Sosei and Allergan have been forced to call a halt to testing of a drug for Alzheimer’s disease and other forms of dementia after cancer was seen in non-human ... It has already completed another phase 1 study and – according to the partners – has
-
Rival Opdivo rejected, Novartis combo gets NICE green light in adjuvant melanoma
The new approval is for patients with stage III disease and in the adjuvant setting, and aims to remove any residual cancer left behind after surgery to remove the tumour and ... BMS has had mixed success in gaining NICE approval for Opdivo across its
-
AZ nabs US approval for new leukaemia drug Lumoxiti
National Cancer Institute (NCI) in the US, the lead investigator in the study. ... Seattle Genetics/Takeda’ s classical Hodgkin lymphoma therapy Adcetris (brentuximab vedotin) and Roche’s Kadcyla (trastuzumab emtansine) for breast cancer.
More from news
Approximately 638 fully matching, plus 1,560 partially matching documents found.
Latest Intelligence
-
Cancer immunotherapy: What's on the horizon?
and ovarian cancer, and some tumours such as pancreatic and prostate cancers have proved resistant to current immunotherapies. ... tumours. Researchers are also investigating whether preventive vaccines could be deployed in people with high-risk cancer
-
Immuno-oncology is fundamentally changing what value means, but how quickly can the pharma marketing, educational and service model change to reflect that?
Immuno-oncology agents have made a space for themselves as the ‘fourth pillar’of cancer therapy with some stunning clinical results.
-
Communication is the key to unlocking the potential of immuno-oncology
David Hunt, CEO, Havas Lynx Group. This new treatment – immuno-oncology (IO) – is revolutionising cancer care. ... I was told [I had cancer] in a language that I didn’t understand.
-
Happy 70th birthday NHS: the next 70 need to be very different
The report states: “Although the gap has closed over the last decade for stroke and several forms of cancer, the mortality rate in the UK among people treated for some of ... the biggest causes of death, including cancer, heart attacks and stroke, is
-
Can new data aggregators shift the balance of power away from pharma?
The best example is probably Jem Rashbass’successful attempt to consolidate NHS cancer data through the National Disease Registration Service as part of Public Health England.
More from intelligence
Approximately 7 fully matching, plus 236 partially matching documents found.
Latest appointments
-
Ipsen hires general manager, Laura Hamill joins Gilead and Orchard expands leadership team
There he oversaw the oncology-focused company's launch in the region, as well as the launch and UK reimbursement of its PARP inhibitor in recurrent ovarian cancer.
-
BMS appoints CCO, Stephen Davies joins Eisai and more
Apeiron expands board. Cancer Immunotherapy company Apeiron has expanded its board, appointing Anderson Gaweco as its chief medical and scientific officer. ... class new treatments for cancer patients and to help transform the company into a world-class
-
Marinomed appoints CFO, Robin Brown is named chair of Medicines Discovery Catapult, Filippo Petti joins Ceylad and Vivienne Fox to chair RFI
He said: “Celyad’s differentiated approach to the field of CAR-T cell therapy could lead to a meaningful impact on the lives of patients battling a broad array of cancers.
-
Industry appointments
As a result, I joined Zelluna because I believe these TCRs provide opportunities for driving differentiated therapeutic benefits in patients fighting solid cancers.”. ... In the longer term, Hassan will lead research activities with the aim to expand
-
Sue Mahony to retire as president of Lilly Oncology
We make medicines that help patients with cancer live longer and what a privilege it’s been to wake up each morning with that as my life’s work.”.
More from appointments
Approximately 5 fully matching, plus 199 partially matching documents found.
Latest from PMHub
-
Patient Engagement for the Life Sciences
He’ s a patient expert himself, he’ s a EUPATI scholar, and he’ s built a virtual patient network for patients with cancer.
-
Genetic counsellors: the new healthcare influencers?
patients. In April 2018, Medicare &Medicaid Services announced patients with advanced cancer will have free access to genetic testing. ... to recommend genetic testing to high-risk breast cancer patients, despite the women asking for tests.
-
Mastering the precision medicine opportunity
Parallel to the increasing number of testing options is the evolving taxonomy of cancer types. ... To date, cancer is diagnosed, treated and measured in relation to the organ of origin in the body.
-
Irritable Bowel Syndrome (IBS) Patient Insights
4). "IBS does not cause cancer, colitis, or any other problems.
-
Bringing the NHS into the 21st century
When gastroenterology registrar Dr Bahman Nedjat-Shokouhi attended to a patient who had spent three months waiting for an outpatient appointment and worrying about a potential cancer diagnosis, he questioned how
More from PMHub
Approximately 33 fully matching, plus 160 partially matching documents found.
Featured jobs
- Medical Writers Required - Hertfordshire
-
Competitive
-
Senior Medical Writer
-
Salary is DOE
-
Account Manager
-
Negotiable
- Integrated Brand/ Digital Senior Account Director, London
-
Excellent package
- Account Director or Senior Account Director
-
Salary TBC
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Scientific Director – Medical Communications - New York or Remot...
-
$100000 - $150000
- Account Director, Medical Communications & Events
-
£50 - 65, 000 according to skills and experience benefits
- Account Director, Healthcare Communications Agency
-
£54, 000- £60, 000
- Senior Strategist/ Planner, Healthcare Marketing, London
-
Excellent package
- Leadership opportunity, Pricing & Market Access, UK, Substan...
-
Substantial six figure package
- Senior Writer, Healthcare Advertising, London
-
Excellent package
- Sudler London - Senior Medical Writer
-
Competitive
-
Healthcare PR Senior Account Manager
-
Salary TBC
- Technical Manager – Developer and Commercial Excellence, Healthc...
-
Excellent package
-
Senior Training Manager - Surrey
-
Competitive Salary &Bonus
- Senior Medical Writer, MedComms Agency
-
£40 - 55, 000 according to skills and experience benefits
-
Sudler London - Account Director
-
Competitive
Subscribe to our email news alerts
- Innovate UK awards £1m for AI drug discovery project
- Kymriah rejected in DLBCL - but NICE wants to keep talking about cost effectiveness
- Biotech leaders jump into US free speech debate
- Viking throws down gauntlet in NASH battle
- Q&A: Jenny Squibbs The best and worst things about working in healthcare comms
- Tox trouble stalls Sosei/Allergan Alzheimer’s drug
PMHub
Pegasus
Pegasus inspires healthy decisions through creative, inspirational and integrated communications. Working with ambitious clients, we deliver big ideas and far-reaching...
Latest intelligence
- PM Society Digital Awards – the power of together
- Our chief executive, Emma Statham, writes about the value of awards and the power of together....
- Seduce anyone in four simple steps
- You know the health of the global economy is dependent on our ability to seduce one another – don’t you? And you know that we need to be able to...
- What Would Jeremy Do? : Assessing the impact of a Corbyn-led Labour government
- GK Strategy are delighted to announce the launch our latest briefing paper entitled ‘What Would Jeremy Do? Assessing the impact of a Corbyn-led Labour government’....
Quick links
Infographics
